Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
Tristan Manalac, 10 Apr 2018
In patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), the drug combination of indacaterol/glycopyrronium (IND/GLY) is more cost-effective than the inhaled combination of salmeterol/fluticasone (SFC), a recent Singapore study has found.
05 Oct 2015
Tigecycline is safe and effective in the treatment of necrotising skin and soft tissue infections due to resistant pathogens in critically ill and antimicrobially pre-treated patients, as reported in a prospective multi-centre non-interventional study.

IL-17A inhibitors superior to other immunomodulators in moderate-to-severe plaque psoriasis

07 Jul 2018
From the survey conducted, it is found that more than 80% of patients with psoriasis have experienced discrimination or humiliation across the world.

Interleukin 17A (IL-17A) inhibitors show better efficacy than ustekinumab in achieving clearance in adults with moderate-to-severe plaque psoriasis, a recent study has shown. Additionally, IL-17A inhibitors are generally more effective than etanercept, adalimumab and apremilast.

The network meta-analysis showed the following targeted immunomodulators in order of increasing relative risk (demonstrating greater likelihood) of achieving a 75-percent improvement on the Psoriasis Area and Severity Index (PASI) relative to placebo: apremilast (6.2), etanercept (9.6), adalimumab (13.0), ustekinumab (14.0), secukinumab (15.4), infliximab (16.2), brodalumab (17.3) and ixekizumab (17.9).

Infliximab, brodalumab and ixekizumab were shown to be statistically superior to apremilast, etanercept, adalimumab and ustekinumab. Furthermore, data from head-to-head studies showed similar results.

A previous network-meta-analysis showed that ixekizumab, secukinumab, brodalumab, guselkumab, certolizumab and ustekinumab, as compared to placebo, were the best choices for achieving PASI 90 in patients with moderate-to-severe psoriasis based on moderate- to high-certainty evidence. [Cochrane Database Syst Rev 2017 Dec 22;12:CD01153

To assess the comparative effectiveness of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis, the investigators conducted a systematic literature review of placebo-controlled and head-to-head randomized trials of eight targeted immunomodulators that evaluated clinical benefits or harm.

In addition, a network meta-analysis adjusted for placebo response was carried out to perform indirect comparisons between agents. A 75-percent improvement on the PASI was the primary outcome.

The present study was limited by mostly short-term evidence (covering 10–16 weeks) and by few direct comparisons, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
Tristan Manalac, 10 Apr 2018
In patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), the drug combination of indacaterol/glycopyrronium (IND/GLY) is more cost-effective than the inhaled combination of salmeterol/fluticasone (SFC), a recent Singapore study has found.
05 Oct 2015
Tigecycline is safe and effective in the treatment of necrotising skin and soft tissue infections due to resistant pathogens in critically ill and antimicrobially pre-treated patients, as reported in a prospective multi-centre non-interventional study.